Palisade Bio (PALI) Equity Average (2011 - 2026)
Palisade Bio (PALI) reported Equity Average of $128.4 million for Q1 2026, up 1902.2% year-over-year from $6.4 million in Q1 2025, and up 93.63% on a QoQ basis from $66.3 million in Q4 2025.
Palisade Bio (PALI) has 16 years of Equity Average data on file, last reported at $128.4 million in Q1 2026.
- Quarterly Equity Average rose 1902.2% year-over-year to $128.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.4 million (up 1902.2% YoY) and the FY2025 annual result came in at $68.4 million, up 627.85% from the prior year.
- Equity Average rose to $128.4 million in Q1 2026 per PALI's latest filing, from $66.3 million in the prior quarter.
- Across five years, Equity Average topped out at $128.4 million in Q1 2026 and bottomed at $2.9 million in Q3 2025.
- The 5-year median for Equity Average is $10.0 million (2024), against an average of $19.5 million.
- The widest annual swing landed in 2025, when Equity Average sank 64.78%; it then soared 1902.2% in 2026.
- Tracing PALI's Equity Average over 5 years: stood at $12.5 million in 2022, then grew by 1.95% to $12.7 million in 2023, then tumbled by 44.48% to $7.0 million in 2024, then surged by 840.37% to $66.3 million in 2025, then soared by 93.63% to $128.4 million in 2026.
- Per Business Quant, the three latest PALI Equity Average figures stand at $128.4 million (Q1 2026), $66.3 million (Q4 2025), and $2.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 128.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128.37 Mn |
| Dec 31, 2025 | 66.30 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | 6.41 Mn |
| Dec 31, 2024 | 7.05 Mn |
| Sep 30, 2024 | 8.28 Mn |
| Jun 30, 2024 | 10.01 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 12.70 Mn |
| Sep 30, 2023 | 14.94 Mn |
| Jun 30, 2023 | 14.77 Mn |
| Mar 31, 2023 | 13.11 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 8.32 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 6.08 Mn |
| Dec 31, 2021 | 5.64 Mn |
| Sep 30, 2021 | -2.76 Mn |
| Jun 30, 2021 | -14.75 Mn |
| Mar 31, 2021 | -18.33 Mn |
| Dec 31, 2020 | -14.72 Mn |
| Sep 30, 2020 | -12.26 Mn |
| Jun 30, 2020 | -10.95 Mn |
| Mar 31, 2020 | -9.28 Mn |
| Dec 31, 2019 | -644,718.50 |
| Sep 30, 2019 | 4.50 Mn |
| Jun 30, 2019 | 2.62 Mn |
| Mar 31, 2019 | 4.66 Mn |
| Dec 31, 2018 | 5.26 Mn |
| Sep 30, 2018 | 5.33 Mn |
| Jun 30, 2018 | 6.39 Mn |
| Mar 31, 2018 | 7.56 Mn |
| Dec 31, 2017 | 10.04 Mn |
| Sep 30, 2017 | 9.63 Mn |
| Jun 30, 2017 | 8.74 Mn |
| Mar 31, 2017 | 10.56 Mn |
| Dec 31, 2016 | 3.77 Mn |
| Sep 30, 2016 | -1.47 Mn |
| Jun 30, 2016 | 333,551.00 |
| Mar 31, 2016 | 2.40 Mn |
| Dec 31, 2015 | 6.94 Mn |
| Sep 30, 2015 | 11.72 Mn |
| Jun 30, 2015 | 16.95 Mn |
| Mar 31, 2015 | 18.54 Mn |
| Dec 31, 2014 | 19.31 Mn |
| Sep 30, 2014 | 22.47 Mn |
| Jun 30, 2014 | 25.46 Mn |
| Mar 31, 2014 | 17.66 Mn |
| Dec 31, 2013 | 8.34 Mn |
| Sep 30, 2013 | 6.34 Mn |
| Jun 30, 2013 | 5.05 Mn |
| Mar 31, 2013 | 6.33 Mn |
| Dec 31, 2012 | 8.04 Mn |
| Sep 30, 2012 | 5.79 Mn |
| Jun 30, 2012 | 3.51 Mn |
| Mar 31, 2012 | 3.10 Mn |
| Dec 31, 2011 | 2.78 Mn |
| Sep 30, 2011 | 5.08 Mn |